Impact of Prior Treatment, ESR1 Mutations, and PI3K Pathway on Elacestrant Outcomes in HR+/HER2- Advanced Breast Cancer
Impact of Prior Treatment, ESR1 Mutations, and PI3K Pathway on E…
191 viewsDec 17, 2024
vumedi.com
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR Advanced Breast Cancer
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcom…
Dec 13, 2024
onclive.com
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER Breast Cancer | OncLive
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER Br…
Dec 11, 2024
onclive.com
The Role of Elacestrant in Breast Cancer | OncLive
The Role of Elacestrant in Breast Cancer | OncLive
Jan 30, 2024
onclive.com
Real-World Data: Elacestrant for ESR1m, ER , HER2- MBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Real-World Data: Elacestrant for ESR1m, ER , HER2- MBC | Targete…
8 months ago
targetedonc.com
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Brea…
Jun 14, 2022
onclive.com
Considering Elacestrant in ESR1 Breast Cancer After CDK4/6 Inhibition | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Considering Elacestrant in ESR1 Breast Cancer After CDK4/6 Inhibi…
Feb 17, 2025
targetedonc.com
The EMERALD Trial: Elacestrant Mechanism of Action, Study Desig…
Nov 9, 2022
targetedonc.com
ADELA Study - Elacestrant Everolimus vs. Elacestrant in ER /…
301 views9 months ago
vumedi.com
3:07
The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advance…
2 weeks ago
onclive.com
2:01
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer …
2 weeks ago
targetedonc.com
Elacestrant + Targeted Therapy for ER+/HER2– Metastatic Breast Can…
2 weeks ago
targetedonc.com
1:44
Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Meta…
1 week ago
onclive.com
ER metastatic breast cancer: Key insights on elacestrant from the la…
11 months ago
apple.com
EMERALD: Elacestrant in ER /HER2- Advanced Breast Cancer | OncLive
Jan 23, 2024
onclive.com
Dr Bardia on the Investigation of Elacestrant vs Endocrine Therapy …
4 weeks ago
onclive.com
Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Can…
4 weeks ago
onclive.com
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Ca…
Dec 22, 2022
onclive.com
Clinical Findings of Elacestrant, an Oral SERD for ER /HER2– Metastat…
Feb 4, 2025
onclive.com
18:01
Elacestrant Combinations in ER /HER2- Locally Advanced or Metas…
6 months ago
onclive.com
6:07
Elacestrant real-world progression-free survival (rwPFS) of adult patie…
2 weeks ago
onclive.com
Tumore: elacestrant nuova terapia in aiuto a pazienti con carcinoma …
Jun 20, 2024
Il Sole 24 ORE
Dr. Bidard on the FDA Approval of Elacestrant in ER /HER2– Metastat…
Feb 8, 2023
onclive.com
Oral SERDs in HR Positive Breast Cancer: Current Role and Patient …
1 month ago
onclive.com
All-Oral Elacestrant Combos Offer “Tremendous” Benefits in Breast …
2 months ago
cancernetwork.com
EMERALD subgroup analysis: Elacestrant in endocrine-sensitiv…
Nov 25, 2024
targetedonc.com
The Role of Elacestrant in HR /HER–- mBC: Insights From the E…
8 months ago
onclive.com
0:50
FDA approves Elacestrant (Orserdu) for ER-positive, HER2-negative, E…
1.3K viewsJan 29, 2023
YouTubemedXclusive Learning
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER Breast …
Dec 12, 2024
targetedonc.com
See more videos
Static thumbnail place holder